SCHEMBL10067295

SCHEMBL10067295

Cc1c(-c2nc3c4cccnc4c4ncccc4c3[nH]2)c2ccccc2n1CC(=O)N1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
GLA P06280 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MAPT P10636 5/20 0.47
TP53 P04637 3/20 0.43
THRB P10828 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41
ALDH1A1 P00352 3/20 0.39
TSHR P16473 3/20 0.39
HSD17B10 Q99714 2/20 0.39
MEN1 O00255 1/20 0.39
HPGD P15428 1/20 0.39
KMT2A Q03164 1/20 0.39
HTT P42858 1/20 0.38
KDM4E B2RXH2 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10067281 1.00 LMNA (0.49) LMNAGLAL3MBTL1MAPTTP53
SCHEMBL10067277 0.99 LMNA (0.50) LMNAGLAL3MBTL1MAPTTP53
SCHEMBL10067306 0.90 TSHR (0.44) LMNAGLAL3MBTL1MAPTTP53
SCHEMBL10067278 0.86 TSHR (0.47) LMNAGLAL3MBTL1MAPTTP53
SCHEMBL10067302 0.80 MAPT (0.48) LMNAL3MBTL1MAPTTP53ALDH1A1
SCHEMBL10067272 0.80 MAPT (0.48) LMNAL3MBTL1MAPTTP53ALDH1A1
SCHEMBL10067267 0.79 MAPT (0.46) LMNAL3MBTL1MAPTTP53ALDH1A1
SCHEMBL10067289 0.75 KDM4E (0.37) LMNAGLAL3MBTL1MAPTNPSR1
SCHEMBL10067355 0.74 LMNA (0.70) LMNAGLAL3MBTL1MAPTTP53
SCHEMBL10067354 0.74 LMNA (0.70) LMNAGLAL3MBTL1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-8148392-B2 2-indolyl imidazo [4,5-d] phenanthroline derivatives and their use in the treatment of cancer LORUS THERAPEUTICS INC. (CA) 2012-04-03 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer APTOSE BIOSCIENCES INC. (CA) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168417-A1 2-Indolyl Imidazo [4,5-d] Phenanthroline Derivatives and Their Use in the Treatment for Cancer FLI1, IKZF3, IKZF2 LMNA 1875/4885GLA 2359/4885L3MBTL1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.